Search results for " Pneumococcal"

showing 10 items of 29 documents

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

Sorveglianza attiva delle patologie pneumococciche invasive dell'età pediatrica: l’esperienza della Regione Sicilia nel triennio 2009-2011

2013

S.pneumoniae is a major cause of morbidity and mortality among children globally. Since 2007 the World Health Organization has recommended anti-pneumococcal vaccination to reduce the burden of invasive pneumococcal diseases (IPD). The aim of this study was to estimate the incidence of IPD in Sicilian children and describe the distribution of serotypes in subjects with IPD following the recent introduction of a universal vaccination program. Active surveillance of IPD (PneumoNet) was carried out in Sicily from 2009 to 2011 by nine reference hospitals (one per province) and one-hundred randomly sampled family pediatricians. Hospital discharge data of participating hospitals were also analyzed…

Active surveillanceMalattia Pneumococcica Invasiva Vaccinazione antipneumococcica Sorveglianza Età Pediatricapneumococcal diseases in Sicilian childrenSettore MED/42 - Igiene Generale E Applicatainvasive pneumococcal disease
researchProduct

Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation

2009

BACKGROUND: Invasive pneumococcal disease is a life-threatening complication after allogeneic stem cell transplantation, and at least 20% of cases occur within 1 year after transplantation. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has limited efficacy, especially during the first year after transplantation. The immune response to the conjugated vaccines is expected to be better than that to the polysaccharide vaccine, but the optimal timing of vaccination is not defined. Our objective was to show that a 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was not inferior when first given 3 months after transplantation, compared with when first given 9 months after trans…

AdultMaleMicrobiology (medical)Pediatricsmedicine.medical_specialtyHeptavalent Pneumococcal Conjugate VaccineTime FactorsAdolescentmedicine.medical_treatmentImmunization SecondaryHematopoietic stem cell transplantationPneumococcal conjugate vaccinePneumococcal VaccinesYoung AdultHeptavalent Pneumococcal Conjugate VaccineHumansMedicineChildImmunization Schedulebusiness.industryPneumococcal 7-Valent Conjugate VaccineMiddle AgedAntibodies BacterialPneumococcal polysaccharide vaccineEuropeVaccinationTransplantationInfectious DiseasesImmunizationImmunologyFemalebusinessImmunosuppressive AgentsStem Cell Transplantationmedicine.drugClinical Infectious Diseases
researchProduct

Assessment of Analysis of Urinary Pneumococcal Antigen by Immunochromatography for Etiologic Diagnosis of Community-Acquired Pneumonia in Adults

2006

ABSTRACT The limitations of conventional microbiologic methods (CMM) for etiologic diagnosis of community pneumococcal pneumonia have made faster diagnostic techniques necessary. Our aim was to evaluate the usefulness of the immunochromatography (ICT) technique for detecting urinary Streptococcus pneumoniae antigen in the etiologic diagnosis of community-acquired pneumonias (CAP). This was a prospective study on in-patients with CAP in a tertiary hospital conducted from October 2000 to March 2004. Apart from using CMM to reach an etiologic diagnosis, we determined pneumococcal antigen in concentrated urine by ICT. We also determined the urinary pneumococcal antigen (UPA) content in patients…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAdolescentClinical BiochemistryImmunologymedicine.disease_causeCommunity-acquired pneumoniaInternal medicineStreptococcus pneumoniaemedicineHumansImmunology and AllergyProspective StudiesAgedAged 80 and overAntigens BacterialChromatographyCOPDbusiness.industryClinical and Diagnostic Laboratory ImmunologyRespiratory infectionMiddle AgedPneumonia Pneumococcalmedicine.diseaseCommunity-Acquired InfectionsPneumoniaPneumococcal infectionsStreptococcus pneumoniaePneumococcal pneumoniaImmunologyImmunologic TechniquesEtiologyFemalebusinessClinical and Vaccine Immunology
researchProduct

Antimeningococcal and antipneumococcal vaccination determinants: A European systematic literature review

2015

Background. ESCULAPIO is a multicenter project, funded by the Italian Centre for Disease Prevention and Control, aimed at implementing communication strategies to improve vaccination knowledge and attitudes among different target populations. Objective. The objective of the Sicilian research unit was, in the first phase, to identify, through systematic literature revision, which vaccination determinants play a role in the uptake of recommended vaccines included in the Italian Vaccination Plan. Design. A systematic literature review was carried out on studies describing the determinants underlying pneumococcal and meningococcal vaccination uptake. The analysis was limited to papers published…

AdultMaleParentsHealth Knowledge Attitudes PracticeAdolescentMeningococcal VaccinesSettore MED/42 - Igiene Generale E ApplicataVulnerable PopulationsHealth Services AccessibilityPneumococcal InfectionsPneumococcal VaccinesVaccination RefusalMeningococcal vaccination; Pneumococcal vaccination; Systematic literature review; Epidemiology; Public Health Environmental and Occupational HealthHumanssystematic literature review meningococcal vaccination pneumococcal vaccinationChildAgedAged 80 and overVaccinationAge FactorsInfantEuropeMeningococcal InfectionsSocioeconomic FactorsChild PreschoolCosts and Cost AnalysisFemale
researchProduct

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

2011

Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes for preventing invasive pneumococcal disease. Objective: The objective of this study was to estimate the potential health benefits, costs, and cost-effectiveness of vaccination with PCV-13 in the Community of Valencia and to generate valuable information for policy makers at regional and country levels. Methods: A decision tree was designed to determine the health and economic outcomes in hypothetical cohorts of vaccinated and unvaccinate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCost effectivenessPharmacoeconomic assessmentCost-Benefit AnalysisPneumococcal conjugate vaccinePneumococcal InfectionsHerd immunityPneumococcal VaccinesIndirect costsYoung AdultEnvironmental healthmedicineHeptavalent Pneumococcal Conjugate VaccineHumansChildAgedAged 80 and overGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfant NewbornInfantMiddle AgedQuality-adjusted life yearVaccinationInfectious DiseasesSpainChild PreschoolCohortMolecular MedicineCost-effectivenessFemalebusinessmedicine.drugVaccine
researchProduct

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza dur…

2013

Background: Since influenza predisposes to bacterial pneumonia caused by Streptococcus pneumoniae, studies have suggested that pneumococcal vaccination might reduce its occurrence during pandemics. We assessed the effectiveness of pneumococcal polysaccharide vaccination alone and in combination with influenza vaccination in preventing influenza hospitalization during the 2009–2010 pandemic wave and 2010–2011 influenza epidemic. Methods: We conducted a multicenter case-control study in 36 Spanish hospitals. We selected patients aged ≥ 18 y hospitalized with confirmed influenza and two hospitalized controls per case, matched according to age, date of hospitalization and province of residence.…

AdultMalemedicine.medical_specialtyAdolescentInfluenza vaccineImmunologymedicine.disease_causePneumococcal VaccinesYoung AdultInternal medicineStreptococcus pneumoniaePandemicInfluenza HumanmedicineImmunology and AllergyHumansYoung adultAgedPharmacologyAged 80 and overbusiness.industryBacterial pneumoniaCase-control studyvirus diseasesMiddle AgedPneumonia Pneumococcalmedicine.diseasePneumococcal polysaccharide vaccineVaccinationHospitalizationInfluenza VaccinesSpainCase-Control StudiesImmunologyCosts and Cost AnalysisFemalebusinessResearch Paper
researchProduct

The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired…

2015

Abstract Introduction Pneumococcal 13-valent vaccine (PCV-13) has a potential role in preventing bacteraemic pneumococcal pneumonia and its complications, but little is known about its ability to specifically prevent respiratory complications. Our aim were to analyse the pneumococcal serotypes associated with the development of respiratory complications and the potential role of PCV-13 in preventing respiratory complications in bacteraemic pneumococcal pneumonia. Material and methods We analysed demographic characteristics, comorbidities, antibiotic resistances and the outcomes of a cohort of 65 vaccine-naive bacteraemic pneumococcal pneumonias, stratified by the pneumococcal serotypes incl…

AdultMalemedicine.medical_specialtyPopulationBacteremiamedicine.disease_causeSerogroupPneumococcal conjugate vaccineHypoxemiaPneumococcal Vaccines03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicineStreptococcus pneumoniaemedicineHumans030212 general & internal medicineIntensive care medicineeducationAgedRetrospective StudiesAged 80 and overCOPDeducation.field_of_studyVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthMiddle AgedPneumonia Pneumococcalmedicine.diseaseCommunity-Acquired InfectionsPneumoniaInfectious DiseasesStreptococcus pneumoniae030228 respiratory systemPneumococcal pneumoniaMolecular MedicineFemalemedicine.symptombusinessmedicine.drugVaccine
researchProduct

Pneumococcus infections: Is the burden still as heavy?

2012

EA MERS CT3 Enjeu 3; International audience; The death rate of invasive pneumococcal infections decreased by 100 fold in one century. This tremendous improvement was due mainly to antibiotic use and multiple attempts at antipneumococcal vaccinations; thus, this was true only for developed countries. However, in France, the incidence has increased, over the last 10 years, in all age classes except for children vaccinated by the heptavalent pneumococcal conjugate vaccine. The incidence of these infections remains high, when associated to some risk factors such as HIV infection, malignant blood diseases, solid cancers, bronchial diseases, or alcohol abuse. The pneumococcal vaccine should be pr…

AdultSerotypeHeptavalent Pneumococcal Conjugate Vaccine[SDV]Life Sciences [q-bio]Immunization SecondaryAlcohol abuseGlobal HealthPneumococcal InfectionsPneumococcal Vaccines03 medical and health sciences0302 clinical medicineRisk FactorsHeptavalent Pneumococcal Conjugate Vaccine[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyHumansMedicineserotype030212 general & internal medicineSerotypingChildinfection invasive à pneumocoque0303 health sciences030306 microbiologybusiness.industrypneumococcal invasive infectionDeveloped CountriesIncidenceMortality rateIncidence (epidemiology)VaccinationAge Factorssérotypemedicine.disease3. Good healthVaccinationPneumococcal infectionsStreptococcus pneumoniaeInfectious DiseasesPneumococcal vaccine[SDE]Environmental SciencesImmunologyDisease SusceptibilityFrancebusinessMédecine et Maladies Infectieuses
researchProduct

Procalcitonin and community-acquired pneumonia (CAP) in children

2015

The role of procalcitonin (PCT) as a biomarker for sepsis in adults is well documented, while its role in infections affecting neonatal children remains controversial. Among these infections, Community-Acquired pneumonia (CAP) has been studied extensively, because it's the second cause of death in children in developing countries, and one of the most frequent causes of hospitalization in industrialized countries. The PubMed database and the Cochrane Library were used to search for the following keywords: CAP, procalcitonin, and children. Thirteen articles were studied to determine the role of PCT in CAP management, specifically its usefulness for distinguishing pneumococcal infections from …

Calcitoninmedicine.medical_specialtyCommunity-acquired pneumoniaCalcitonin Gene-Related PeptideClinical BiochemistryCochrane LibraryBiochemistryProcalcitoninSepsisCommunity-acquired pneumoniamedicineHumansProtein PrecursorsChildIntensive care medicineChildrenCause of deathPediatric CAPbusiness.industryBiochemistry (medical)BiomarkerGeneral MedicinePneumonia Pneumococcalmedicine.diseaseAnti-Bacterial AgentsCommunity-Acquired InfectionsBiomarkers; Children; Community-acquired pneumonia; PCT; Pediatric CAP; ProcalcitoninPneumoniaPneumococcal infectionsBiomarker (medicine)PCTbusinessProcalcitoninBiomarkershormones hormone substitutes and hormone antagonistsClinica Chimica Acta
researchProduct